NCT03706911View on ClinicalTrials.gov

Study to Evaluate Safety, Tolerability and Pharmacokinetics of VM-1500A-LAI Single and Multiple Ascending Doses in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

January 21, 2019

Primary Completion Date

March 27, 2020

Study Completion Date

May 18, 2020

Conditions
HIV-1-infection
Interventions
DRUG

VM-1500A-LAI

VM-1500A (parent drug of elsulfavirine) IM injection dosage form

Trial Locations (1)

119991

Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow

Sponsors

Lead Sponsor

Viriom
All Listed Sponsors
lead

Viriom

INDUSTRY

NCT03706911 - Study to Evaluate Safety, Tolerability and Pharmacokinetics of VM-1500A-LAI Single and Multiple Ascending Doses in Healthy Subjects | Biotech Hunter | Biotech Hunter